N-cyclohexyl-2,4-dihydroxy-3,3-dimethylbutyramide | 16424-76-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-cyclohexyl-2,4-dihydroxy-3,3-dimethylbutyramide
• 英文别名: N-Pantoyl-cyclohexylamin；N-cyclohexyl-DL-pantamide；N-Cyclohexyl-DL-pantamid；(+/-)-2,4-Dihydroxy-3,3-dimethyl-buttersaeure-cyclohexylamid；N-Cyclohexyl-2,4-dihydroxy-3,3-dimethyl-butyramide；N-cyclohexyl-2,4-dihydroxy-3,3-dimethylbutanamide
• CAS: 16424-76-3
• 化学式: C₁₂H₂₃NO₃
• mdl: MFCD00448753
• 分子量: 229.32
• InChiKey: MEBNRFZEMFBDLA-UHFFFAOYSA-N

物化性质

• 熔点：
  111 °C
• 沸点：
  469.1±38.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-cyclohexyl-2,4-dihydroxy-3,3-dimethylbutyramide 在 重铬酸吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以78%的产率得到1-cyclohexyl-4,4-dimethylpyrrolidine-2,3,5-trione
  参考文献：
  名称：

  Enantioselective hydrogenation of pyrrolidine-2,3,5-triones over the Pt–cinchonidine system

  摘要：

  1- and I-Substituted pyrrolidine-2,3,5-triones 5, 6 and 9 have been synthesized and hydrogenated to 3-hydroxy derivatives 10-12 with 17-91% ee using a 5 wt% Pt/Al2O3 catalyst in the presence of small amounts of cinchonidine. The influence of substituents on the enantioselectivity is discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00499-6
• 作为产物：
  描述：

  环己胺 、 DL-泛酰内酯 生成 N-cyclohexyl-2,4-dihydroxy-3,3-dimethylbutyramide
  参考文献：
  名称：

  泛酸衍生物。

  摘要：

  DOI：

  10.1021/jm00313a034

文献信息

• Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1
  申请人：Aicher Thomas Daniel

  公开号：US20080275043A1

  公开（公告）日：2008-11-06

  The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

  本发明公开了具有11beta-HSD type 1拮抗活性的化合物的公式I：（I），以及制备这种化合物的方法。在另一实施例中，本发明公开了包含公式I化合物的制药组合物，以及将公式I和组合物用作药物治疗糖尿病，高血糖，肥胖症，高血压，高脂血症，综合征X和与高血糖有关的其他疾病的用途。
• CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：AICHER Thomas Daniel

  公开号：US20100184764A1

  公开（公告）日：2010-07-22

  The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

  本发明揭示了具有11beta-HSD type 1拮抗活性的I式化合物：（I），以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包括I式化合物的制药组合物，以及将I式和组合物用作药物治疗糖尿病，高血糖，肥胖症，高血压，高脂血症，X综合症和其他与高血糖有关的疾病的用途。
• Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
  申请人：Eli Lilly and Company

  公开号：US07713979B2

  公开（公告）日：2010-05-11

  The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

  本发明公开了具有11beta-HSD类型1拮抗活性的I式化合物(I)，以及制备这些化合物的方法。在另一实施例中，本发明公开了包含I式化合物的药物组合物，以及将I式化合物和组合物用作药物治疗糖尿病、高血糖、肥胖症、高血压、高脂血症、X综合症以及与高血糖相关的其他病症的用途。
• WO2006/49952
  申请人：——

  公开号：——

  公开（公告）日：——
• Arris et al., Journal of the Chemical Society, 1956, p. 4968,4973
  作者：Arris et al.

  DOI：——

  日期：——